Re-Thinking Oncology HTAs: the (Growing) Role of Non-OS Endpoints

In a recent article published on Pharmaceutical Executive, Anais Frappe and Mattia Belloni explore the role of non-OS endpoints, and advocate for a more systematic and balanced recognition of these endpoints, alongside OS, in HTAs.